Research programme: melanocortin-4 receptor antagonists - BioLineRx

Drug Profile

Research programme: melanocortin-4 receptor antagonists - BioLineRx

Alternative Names: BL-6020; SNT207707; SNT209858

Latest Information Update: 03 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MyoContract
  • Developer BioLineRx
  • Class Small molecules
  • Mechanism of Action Melanocortin type 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cachexia

Most Recent Events

  • 14 Oct 2010 BioLineRx licenses the melanocortin-4 receptor antagonists research programme from Santhera Pharmaceuticals
  • 07 Dec 2009 Pharmacodynamics, pharmacokinetics and adverse events data from a preclinical trial in Cachexia released by Santhera Pharmaceuticals
  • 16 Mar 2009 This programme is available for licensing worldwide (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top